Celon Pharma Future Growth
Future criteria checks 1/6
Celon Pharma is forecast to grow earnings and revenue by 56.9% and 7% per annum respectively. EPS is expected to grow by 72.4% per annum. Return on equity is forecast to be -4.7% in 3 years.
Key information
56.9%
Earnings growth rate
72.37%
EPS growth rate
| Pharmaceuticals earnings growth | 11.3% |
| Revenue growth rate | 7.0% |
| Future return on equity | -4.68% |
| Analyst coverage | Low |
| Last updated | 28 Nov 2025 |
Recent future growth updates
Recent updates
Celon Pharma S.A. (WSE:CLN) Could Be Riskier Than It Looks
Mar 06
Statutory Earnings May Not Be The Best Way To Understand Celon Pharma's (WSE:CLN) True Position
Nov 28A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price
Aug 21Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates
Sep 24Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans
Jul 13We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow
Nov 04We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth
Aug 04Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly
May 23Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)
Mar 02Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
Feb 09
Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?
Jan 20Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain
Dec 24Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet
Dec 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 317 | -11 | 106 | 42 | 1 |
| 12/31/2027 | 282 | -25 | -36 | 32 | 2 |
| 12/31/2026 | 242 | -25 | -27 | 26 | 3 |
| 12/31/2025 | 261 | 0 | -47 | 103 | 3 |
| 9/30/2025 | 226 | -122 | -41 | 0 | N/A |
| 6/30/2025 | 206 | -69 | -53 | -9 | N/A |
| 3/31/2025 | 216 | -44 | -43 | -17 | N/A |
| 12/31/2024 | 206 | -34 | -34 | -11 | N/A |
| 9/30/2024 | 210 | 19 | -33 | -17 | N/A |
| 6/30/2024 | 208 | -45 | -12 | 6 | N/A |
| 3/31/2024 | 210 | -28 | -23 | 2 | N/A |
| 12/31/2023 | 215 | -28 | -41 | -8 | N/A |
| 9/30/2023 | 214 | -25 | -31 | 7 | N/A |
| 6/30/2023 | 211 | -30 | -53 | -16 | N/A |
| 3/31/2023 | 196 | -47 | -42 | -8 | N/A |
| 12/31/2022 | 194 | -39 | -39 | -5 | N/A |
| 9/30/2022 | 191 | -31 | -39 | -10 | N/A |
| 6/30/2022 | 186 | -28 | -11 | 32 | N/A |
| 3/31/2022 | 191 | -17 | -17 | 25 | N/A |
| 12/31/2021 | 196 | -12 | 3 | 44 | N/A |
| 9/30/2021 | 186 | -11 | 7 | 60 | N/A |
| 6/30/2021 | 185 | -2 | 3 | 57 | N/A |
| 3/31/2021 | 170 | 0 | -18 | 71 | N/A |
| 12/31/2020 | 157 | -1 | -28 | 72 | N/A |
| 9/30/2020 | 142 | 4 | -58 | 37 | N/A |
| 6/30/2020 | 128 | 5 | -88 | 6 | N/A |
| 3/31/2020 | 109 | 3 | -85 | -19 | N/A |
| 12/31/2019 | 102 | 12 | -70 | -5 | N/A |
| 9/30/2019 | 110 | 17 | -69 | 6 | N/A |
| 6/30/2019 | 118 | 23 | N/A | 15 | N/A |
| 3/31/2019 | 124 | 29 | N/A | 37 | N/A |
| 12/31/2018 | 125 | 30 | N/A | 28 | N/A |
| 9/30/2018 | 116 | 30 | N/A | 27 | N/A |
| 6/30/2018 | 109 | 26 | N/A | 34 | N/A |
| 3/31/2018 | 107 | 28 | N/A | 26 | N/A |
| 12/31/2017 | 107 | 26 | N/A | 25 | N/A |
| 9/30/2017 | 129 | 22 | N/A | 18 | N/A |
| 6/30/2017 | 127 | 24 | N/A | 23 | N/A |
| 3/31/2017 | 115 | 27 | N/A | 28 | N/A |
| 12/31/2016 | 129 | 38 | N/A | 21 | N/A |
| 9/30/2016 | 111 | 42 | N/A | 34 | N/A |
| 12/31/2015 | 108 | 37 | N/A | 52 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CLN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CLN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CLN's revenue (7% per year) is forecast to grow faster than the Polish market (4.3% per year).
High Growth Revenue: CLN's revenue (7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLN is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/07 03:25 |
| End of Day Share Price | 2026/01/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celon Pharma S.A. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Vladimira Urbankova | Erste Group Bank AG |